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Abstract
Ovarian serous carcinoma (OSC) is the most common and lethal histologic type of ovarian epithelial malignancy.
Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in
the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established
tumor-suppressor genes have not been identified. Using a genome-wide screen of DNA copy number alterations in
36 primary OSCs, we identified two tumors with apparent homozygous deletions of the NF1 gene. Subsequently,
18 ovarian carcinoma–derived cell lines and 41 primary OSCs were evaluated for NF1 alterations. Markedly re-
duced or absent expression of Nf1 protein was observed in 6 of the 18 cell lines, and using the protein truncation
test and sequencing of cDNA and genomic DNA, NF1 mutations resulting in deletion of exons and/or aberrant
splicing of NF1 transcripts were detected in 5 of the 6 cell lines with loss of NF1 expression. Similarly, NF1 altera-
tions including homozygous deletions and splicing mutations were identified in 9 (22%) of 41 primary OSCs. As
expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway
activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels
of GTP-bound Ras (cell lines). The TP53 tumor-suppressor gene was mutated in all OSCs with documented NF1
mutation, suggesting that the pathways regulated by these two tumor-suppressor proteins often cooperate in the
development of ovarian carcinomas with serous differentiation.
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Introduction
Ovarian epithelial cancer (OvCa) is the most lethal type of gynecologic
cancer in much of the industrialized world. It is a morphologically and
biologically heterogeneous disease. Morphological criteria define four
major types of primary ovarian adenocarcinomas—serous, mucinous,
endometrioid, and clear cell. Molecular studies have offered support
for the notion that the different histologic types of OvCas likely
represent distinct disease entities. Ovarian serous carcinoma (OSC)
is the most common histologic type of epithelial OvCa, comprising
roughly 70% of diagnoses and almost always presents at advanced
stage [1]. Mutations of TP53 and dysfunction of the Brca1 and/or
Abbreviations: OSC, ovarian serous carcinoma; OvCa, ovarian epithelial cancer; PTT,
protein truncation test
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Brca2 tumor-suppressor proteins have been implicated in the molecu-
lar pathogenesis of a large fraction of OSCs [2–7].
However, relatively little is known about other somatic genetic
alterations that are present in a substantial fraction of OSCs. Recent
comprehensive sequence-based analyses of somatic mutations in po-
tentially oncogenic kinases in OvCa suggest that a number of genes
encoding kinases may each be mutated at low frequency in OSCs,
such as the LRRK2, STK36, ALPK2, and AKT1 genes (see http://
www.sanger.ac.uk/genetics/CGP/Studies/Kinases/) [8,9]. In addi-
tion, despite the fact that the TP53 gene is somatically mutated in
60% or more of OSCs and the BRCA1 and/or BRCA2 genes are
inactivated by genetic and/or epigenetic mechanisms in more than
of 80% of OSCs, prior studies have not offered supporting evi-
dence for the notion that somatic mutations in other well-established
tumor-suppressor genes, such as the retinoblastoma (RB1), neuro-
fibromatosis type 1 or type 2 (NF1 and NF2, respectively), Wilms
tumor 1 (WT1), phosphatase and tensin homolog (PTEN ), or the
adenomatous polyposis coli (APC ) genes, are common in OSCs.
Our initial genome-wide analysis of DNA copy number alterations
in 36 primary OSCs identified two tumors with apparent homo-
zygous deletions of the NF1 gene and several additional tumors with
suspected hemizygous loss of NF1. Prompted by this finding, we
screened 18 OvCa cell lines and 41 primary OSCs for NF1 altera-
tions. We report here that mutational defects leading to reduced or
absent Nf1 expression are common in the OvCa primary tumor speci-
mens and cell lines analyzed and lead to Ras pathway activation. In
addition, we found that all tumors with documented NF1 alterations
also harbored mutations of the TP53 tumor-suppressor gene, sug-
gesting the pathways regulated by these two tumor-suppressor pro-
teins often cooperate in OSC pathogenesis.
Materials and Methods
Tumor Samples
Forty-one OSC samples were analyzed in this study, including
18 tumors from the Cooperative Human Tissue Network/Gynecologic
Oncology Group Tissue Bank (Columbus, OH), 2 tumors from the
New York Presbyterian Hospital (Weill Medical College of Cornell
University), 11 tumors from the University of Michigan Health
System, and 10 tumors from the Kumamoto University Hospital
(Kumamoto, Japan). Primary tumor tissues were manually dissected
with microscope guidance to ensure that each tumor sample contained
a minimum of 70% tumor cells. Analysis of tissues from human sub-
jects was approved by the University of Michigan’s Institutional Review
Board (IRB-MED 2001-0568 and 1999-0428).
Cell Lines
The OSC-derived cell lines SKOV-3 and CAOV3 [10] and TOV-
21G (derived from a clear cell carcinoma) and the colorectal carci-
noma cell line HCT116 were obtained from the American Type
Culture Collection (Manassas, VA). Ovarian serous carcinoma cell
lines HOC-1, HOC-7, HOC-8, and HEY [11,12] were a gift from
L. Dubeau (USC School of Medicine, Los Angeles, CA). Ovarian
carcinoma cell lines (histologic type not specified) A1847, A2780,
OVCAR-4, OVCAR-5, OVCAR-8, and OVCAR-10 and OSC-
derived cell lines PEO1 and PEO4 [13] were a gift from T. Hamilton
(Fox Chase Cancer Center, Philadelphia, PA). Ovarian serous carci-
noma cell lines OVCA420, OVCA429, OVCA432, and DOV13
[10] were a gift from D. Fishman (Northwestern University, Chicago,
IL). IOSE-80 ovarian surface epithelial cells immortalized with SV40
large T antigen were a gift from N. Auersperg (University of British
Columbia, Vancouver, Canada). All cell lines were maintained in
DMEM with 10% FBS.
DNA, RNA, and cDNA Preparation
DNA, RNA, and cDNA were prepared using standard tech-
niques. Briefly, genomic DNA was isolated from cultured cells or
frozen tissue sections using SDS/proteinase K digestion followed
by phenol/chloroform extraction. Total RNA was extracted from
cultured cells or frozen tissue sections with Trizol (Invitrogen, San
Diego, CA) according to the manufacturer’s protocol. First-strand
cDNA was synthesized from DNaseI-treated mRNA samples using
random hexamer primers (Amersham Biosciences, Piscataway, NJ)
and Superscript II (Invitrogen).
Representational Oligonucleotide Microarray Analysis
and Data Analysis
Microarrays bearing 42,000 oligonucleotides designed to hy-
bridize Bgl-II restriction fragments of human genome were custom-
synthesized by Nimblegen Systems (Madison, WI) [14]. Briefly, tumor
and normal human/male genomic DNA (1 μg each) were digested by
Bgl-II enzyme (New England Biolabs, Ipswich, MA), and purified by
QIAquick polymerase chain reaction (PCR) purification kit (Qiagen,
Valencia, CA), followed by overnight ligation with the adapters (Bgl-
12: gatctgctgcgt, Bgl-24: tcagcatcgagactgaacgcagca) to provide an
anchoring site for subsequent PCR amplification to generate ge-
nome representations. Subsequent steps of genome representation am-
plification, array hybridization, and data acquisition/analysis were
performed essentially as previously described [15]. The hybridized
microarrays were scanned with an Axon 4000B scanner (Molecular
Devices, Sunnyvale, CA) with pixel size set to 5 μm.
Southern Blot Analysis
For Southern blot analysis, 10 μg of DNA was digested with EcoRI
for 12 to 18 hours at 37°C. The digested DNA was separated in
0.8% agarose gels and transferred overnight to positively charged
nylon membranes (Hybond; Amersham Biosciences). Hybridization
was carried out in Rapid-hyb buffer (Amersham Biosciences) to [α-
32P]dCTP-labeled probes using standard procedures as described
previously [16]. Three probes located at different positions within
the NF1 locus and a control probe on the same chromosomal arm
(DHX40 at 17q23.1) were used. The oligonucleotide sequences used
to generate each probe are provided in Table W1.
Northern Blot Analysis
Ten micrograms of total RNA was separated in 0.9% agarose gels
containing formaldehyde and transferred to Hybond-N+ membranes
(Amersham Biosciences). NF1 and GAPDH probes were generated
by PCR and labeled with 32P-dCTP with a random primer kit
(Invitrogen). The NF1-specific probe corresponding to nucleotides
5999 to 6658 (NM_001042492) of the human NF1 cDNA and
the GAPDH control probe were amplified using the primer sequences
indicated in Table W1. Northern blot hybridization to 32P-labeled
probes was carried out by standard methods. Membranes were ex-
posed to phosphor-imager screens and scanned by phosphorimager
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(Molecular Dynamics, Sunnyvale, CA). The arbitrary units for inten-
sity of photon emissions represent the level of NF1 mRNA normalized
to GAPDH.
Protein Truncation Test
The protein truncation test (PTT) assay was performed as de-
scribed by Heim et al. [17]. Briefly, 2 to 5 μg of mRNA was reverse-
transcribed, and the entire NF1 cDNA was analyzed using the TNT
Quick Coupled Transcription/Translation system (Promega Corp.,
Madison, WI) in overlapping segments using five pairs of primers
(Table W1). The RT-PCR products were transcribed in vitro, and then
in vitro translation was performed in the presence of 35S-methionine.
The PTT samples were separated on 4% to 20% SDS-PAGE gels,
which were dried and subjected to autoradiography. For each sample
with aberrant PTT product(s), the corresponding regions of cDNA
and, in most cases, genomic DNA, were amplified and sequenced.
The primers used for amplification and sequencing of individual exons
were those described by Schirinzi et al. [18].
Western Blot Analysis
Cells were lysed in radioimmunoprecipitation assay lysis buffer
[50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.5% de-
oxycholate, 0.1% SDS] containing complete protease inhibitor cock-
tail (Roche, Indianapolis, IN). The protein concentration was analyzed
by bicinchoninic acid assay (Pierce, Rockford, IL). Subsequently,
100 μg of each cell lysate was separated on a 4% to 20% SDS-PAGE
gel and then transferred to Immobilon P membranes (Millipore,
Bedford, MA) by semidry electroblotting. Western blot analysis was
carried out using anti-Nf1 antibody at a 1:1000 dilution (sc-67; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA). Expression of β-actin was
used as a loading control and was detected with anti-actin polyclonal
antibody (Sigma-Aldrich, St. Louis, MO) at a dilution of 1:1000. The
horseradish peroxidase–conjugated goat anti–rabbit immunoglobulin
(Pierce) was used at a 1:10,000 dilution. Antigen-antibody complexes
were detected by enhanced chemiluminescence (ECL; Amersham
Biosciences) and exposure to X-Omat film (Kodak, Rochester, NY).
The cell line HCT116 is known to have frameshift mutations in
both NF1 alleles and hence serves as a control for extracts lacking
Nf1 expression [19].
Ras Activation Assay
Levels of activated Ras in selected cell lines were detected with a
Ras activation assay kit (Upstate USA, Inc., Charlottesville, VA) per
the manufacturer’s protocol. Briefly, cells were starved in serum-free
DMEM for 3 hours at 37°C. Cells were lysed, and the protein con-
centration was determined by the bicinchoninic acid method. A total
of 250 μg of cellular lysate was incubated with Raf-1 RBD agarose
(10 μl) at 4°C for 45 minutes. The agarose pull-downs were washed
three times with lysis buffer, boiled with 2× Laemmli sample buffer,
and separated on SDS-PAGE gels, followed by Western blot analysis
using a monoclonal anti-Ras antibody at a 1:3000 dilution (Upstate
USA, Inc.). To determine the levels of total Ras protein, 15 μg of
total cellular lysates was electrophoresed on polyacrylamide gels fol-
lowed by immunoblot analysis with the monoclonal anti-Ras anti-
body. Subsequently, the blot was reprobed with anti-actin antibody
(Sigma-Aldrich) at a dilution of 1:1000.
Figure 1. ROMA detects homozygous deletions including NF1 in primary OSCs. Using a moving average algorithm of the window of five
data points, the raw DNA copy number ratio of tumor over normal reference was smoothened and plotted against the chromosomal
position of all the oligonucleotide probes on chromosome 17 for tumor samples OSC-1 (A) and OSC-11 (B). The arrows point at the
apparent homozygous deletions including the NF1 locus. To provide greater resolution of the deleted region, an area of 4 Mb across the
NF1 deletion is shown for OSC-1 (C) and OSC-11 (D). Location of NF1 is as indicated in panel (D). Chromosomal positions of ROMA
oligonucleotide probes were based on the NCBI build 34 (hg16 assembly).
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Immunohistochemical Analysis of p53 and pMAPK
Five-micrometer sections were cut from blocks of formalin-fixed
paraffin-embedded tissue for routine staining with hematoxylin and
eosin. Immunohistochemical staining was conducted using the avidin-
biotin-peroxidase method. Sections were immunostained using rabbit
polyclonal anti–active MAPK Pab at a 1:200 dilution (pTEpY; Promega
Corp.) or with mouse monoclonal anti–TP53 antibody (1:100 dilu-
tion, clone D0-7; Invitrogen). Immunostaining for nuclear and/or
cytoplasmic pMAPK was scored on a four-tiered scale for intensity
(−, absent; +, weak; ++, moderate; and +++, strong). Immunostaining
for nuclear TP53 was scored as negative (absent, weak, or focal) or
positive (strong and diffuse).
Sequencing of TP53, KRAS, and BRAF
Mutational analyses of the TP53 (exons 3-10), KRAS (exon 2),
and BRAF (exons 11 and 15) genes were performed in the OSC sam-
ples using published and custom primer sequences as indicated in
Table W1. Pearson’s product moment correlation analysis (using
the S-Plus statistical package) was used to measure the correlation
between TP53 and NF1 mutations in the primary OSCs, and the
Fisher’s exact test was used to determine the significance of the asso-
ciation between mutations of these genes.
Results
A Subset of Primary OSCs Harbor Homozygous Deletions
of the NF1 Gene
We pursued comprehensive analyses of DNA copy number altera-
tions in 78 primary OvCas using a representational oligonucleotide
microarray analysis (ROMA) approach. The full analysis of DNA copy
number changes in OvCas will be presented elsewhere. However, 2 of
36 OSCs studied (OSC-1 and OSC-11) were found to show copy
number changes consistent with potential homozygous deletions in-
volving the NF1 locus at chromosome band 17q11.2. Figure 1 shows
moving average plots depicting the homozygous deletions identified
by ROMA in these two tumors. To generate these plots, a moving win-
dow of five data points was used to average the rawDNA copy number
along the whole chromosome 17. On the basis of the ROMA data,
four additional tumors (OSC-2, OSC-5, OSC-24, and OSC-25)
showed evidence for loss of one NF1 allele. To confirm the presence
of NF1 homozygous deletions, we performed Southern blot studies of
selected primary OSCs, including the tumors with apparent homozy-
gous or hemizygous deletions of the NF1 gene. The NF1 gene is very
large, spanning nearly 300 kb, with 57 common exons and at least 3
alternatively spliced exons. Three DNA sequence probes derived from
widely spaced regions of theNF1 locus were used for the Southern blot
Figure 2. Southern blot analysis reveals homozygous deletions of NF1 in primary OSCs. (A) Southern blot analysis of EcoRI-digested OSC
DNAsamplesusing threeprobesat different locationswithin theNF1gene. Tocontrol for loading, theblotswere rehybridizedwith a probe for
DHX40, which lies telomeric toNF1 on chromosome 17q. (B) The relative location of each probe on chromosome 17 is shown in the diagram.
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analysis, and the NF1-specific hybridization intensities were compared
to those for a control probe (DHX40), located telomeric to NF1 on
chromosome 17q. Genomic DNA from tumor OSC-11 did not show
a detectable hybridization signal with any of the threeNF1 probes (Fig-
ure 2), suggesting that both chromosome 17q deletions in this tumor
affected the entire NF1 locus. OSC-1 showed no hybridization signal
for probe 2 or 3 but showed hybridization to probe 1, whereas DNA
from OSC-5 did not hybridize with probe 1 or 2 but retained NF1
sequences detected by probe 3. These results indicate that, in tumor
OSC-1, there was a homozygous deletion involving a telomeric region
of theNF1 gene (i.e., the 5′ end of theNF1 gene), and in tumorOSC-5,
there was a homozygous deletion of a more centromeric (3′) portion of
theNF1 gene. OSC-5 is one of the primary tumors suspected to have at
least hemizygous deletion of NF1 based on ROMA.
Reduced or Absent NF1 Gene and Protein Expression
in OvCa Cell Lines
To explore the possibility that the NF1 gene might be inactivated
in a significant fraction of OSCs, we pursued analysis of NF1 tran-
script and protein levels in a panel of 18 human OvCa cell lines.
Twelve of the ovarian cancer cell lines are known to have been de-
rived from OSCs [10–13]. The other six lines were derived from
ovarian carcinomas of unspecified histologic subtype. However, given
the frequency of OSC as a fraction of all OvCa diagnoses, many of
the lines of unspecified type are likely to have been derived from se-
rous tumors. NF1 transcripts range in size from 11 to 13 kb owing to
alternative splicing and differences in the extent of 3′ untranslated
sequences [20,21]. On the basis of Northern blot analysis, NF1 tran-
script levels varied significantly among the ovarian carcinoma cell
lines, with high expression seen in OVCA420 and OVCA432 and
minimal NF1 gene expression seen in several other cell lines includ-
ing DOV13, HOC-7, HOC-8, OVCA429, A1847, A2780, and
CAOV3 (Figure 3A). To assess expression of the Nf1 protein in
the OvCa lines, Western blot analysis with an antibody directed
against a carboxyl-terminal region of the Nf1 protein was pursued
(Figure 3B). The HCT116 colon carcinoma cell line is known to
have frameshift mutations in both NF1 alleles and hence serves as
a negative control for Nf1 expression [19]. Of the 18 OvCa lines
Figure 3. Expression of NF1 is reduced or absent in several ovarian carcinoma cell lines. (A) NF1 transcripts in the indicated cell lines
were detected by Northern blot analysis, using expression of GAPDH as a loading control. Relative expression of NF1 in each cell line
normalized to GAPDH (arbitrary units) is indicated. (B) Nf1 protein levels in the same cell lines were determined by Western blot analysis
using an anti–Nf1 antibody. Detection of actin was used as a loading control.
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examined, five cell lines (DOV13, OVCA429, PEO4, A1847, and
CAOV3) had essentially undetectable Nf1 protein expression. One ad-
ditional cell line, PEO1, expressed only very minimal levels of Nf1.
The findings suggest that perhaps more than one-third of OSCs might
have mutational or epigenetic defects leading to NF1 inactivation.
NF1 Mutations Are Present in OvCa Lines with Reduced
or Absent Nf1 Expression
Protein truncation test assays were performed on the six OvCa
lines (OVCA429, CAOV3, DOV13, PEO4, PEO1, and A1847)
with low or absent Nf1 protein expression to ascertain a molecular
basis for altered expression in the lines. cDNA was prepared from
mRNA extracted after cells were cultured in the presence of puro-
mycin, which inhibits nonsense-mediated decay of mRNA [22].
The entire NF1 coding region was examined by in vitro transcrip-
tion and translation in five overlapping fragments (segments I-V).
We were able to detect aberrant PTT products in five of the six cell
lines, either as altered sized RT-PCR fragments (data not shown) or
as truncated peptide fragments in segments I, II, or III in the PTT
assay (Figure 4A). The corresponding cDNA and genomic DNA
fragments from each cell line were cloned and sequenced (data sum-
marized in Table 1). The cell line OVCA429 shows an aberrant
PTT product in segment II, and the corresponding cDNA and ge-
nomic DNA both show a 17 base pair (bp) deletion in exon 17. The
CAOV3 line has an aberrant PTT product in segment III, and se-
quencing of the corresponding cDNA revealed deletion of exons 22
and 23-1 and inclusion of 102 bp from the intron downstream of
exon 23-2. We were unable to amplify these exons from genomic
DNA by PCR, but amplification using adjacent intron primers re-
vealed deletion of 1448 bp from this region. The A1847 line also
showed an aberrant peptide in segment III, and the cDNA had an
insertion of 101 bp from the intron downstream of exon 23-2. Se-
quencing of genomic DNA from A1847 revealed a single nucleotide
change (C to G) within this cryptic exon, but the mechanism by
which this change may lead to inclusion of intronic sequences in
the NF1 transcript is not clear. DOV13 has a splicing mutation
at the +1 position of exon 23-1, resulting in deletion of exon 23-1 from
the cDNA. A germ line NF1 mutation identical to the presumed
somatic mutation in DOV13 has been reported earlier [23]. In the
cell line PEO4, PCR amplification of cDNA segment I yielded a
RT-PCR product that was smaller than expected (data not shown).
Our inability to detect a corresponding truncated protein fragment in
the PTT assay is likely caused by the very small size of the predicted
protein product (≈12 kDa). Sequencing of the cDNA revealed deletion
of the entirety of exon 4a, and at the genomic level, mutation at the
splice junction of exon 4a (−2, acceptor site, A to T), which leads to
the skipping of this exon. Mutation at the same site in this splice junc-
tion (A to G) has also been reported previously [24]. The PTT assay
failed to detect any mutations in PEO1 cells. This result is perhaps not
unexpected, because a previous study that screened for NF1 germ line
mutations using PTTonly had a combined mutation detection rate of
56% [25]. Overall, our studies provide evidence for Nf1 inactivation
in 6 (33%) of 18 OvCa lines evaluated, with definitive inactivating
mutations identified in 5 of the 6 lines.
NF1 Mutations Are Present in Primary OSCs
We screened a collection of 41 OSCs (including 29 of the 36 OSCs
evaluated by ROMA) for NF1 mutations using the PTT assay. Aber-
rant PTT products affecting segment III, IV, or V were detected in
six tumors (Figure 4B and Table 1). Sequencing of the cDNA corre-
sponding to the aberrant PTT products identified aberrant transcripts
in all six cases. cDNA from two of the tumors, OSC-2 and OSC-35,
showed duplications of exons 24 to 27b (662 bp), whereas OSC-25
has deletion of exons 22 and 23-1. OSC-24 and OSC-32 showed
deletions of exons 30 and 31, respectively. Finally, OSC-18 had an in-
sertion of 178 bp corresponding to the entire intron between exons 44
and 45. Chromatograms of NFI cDNA sequence alterations in repre-
sentative cell lines and primary tumors are shown in Figure 5. Geno-
mic DNA isolated from OSC-24 revealed a deletion of 34 nucleotides
Figure 4. The PTT assay shows truncated Nf1 peptides in ovarian
carcinoma cell lines and primary tumors. (A) PTT was performed
using five overlapping cDNA segments encompassing the entire
NF1 coding region. Representative examples of truncated pep-
tides in segments II and III from the indicated cell lines are shown.
The TOV21G cell line expresses normal levels of full-length NF1,
and it was used to determine the size of the expected (normal)
PTT products in each segment. (B) Representative examples of
truncated peptides in Segments III, IV and V from the indicated
OSC samples are shown. The TOV21G cell line expresses normal
levels of NF1, and it was used to determine the size of the ex-
pected (normal) PTT products in each segment.
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encompassing the 5′ splice site of exon 30, with an insertion of ATG
in its place. Genomic DNA sequencing of the corresponding NF1
exons and exon-intron boundaries in the other tumors failed to reveal
mutations. This might reflect the likelihood that a significant fraction
of mutations that alter appropriate splicing of NF1 transcripts are dis-
tant from the intron-exon boundaries; these mutations presumably
create novel splice sites or activate cryptic splice sites within exonic
or intronic sequences [26]. Alternatively, splicing errors have also been
shown to occur in the absence of identifiable sequence alterations
in the NF1 gene, with tumors showing nearly twice the amount of
aberrant transcript as normal tissues [27]. Overall, we were able to
document NF1 alterations in 9 (22%) of 41 primary OSCs, including
three tumors with homozygous deletions of sizable portions of the
NF1 gene and six tumors with localized mutations leading to prema-
ture truncation of the Nf1 protein. Three of these six tumors also
showed evidence for hemizygous loss of NF1 based on ROMA.
The Ras Pathway Is Activated in Ovarian Carcinoma Cell
Lines and Primary OSCs with NF1 Mutations
The Nf1 (neurofibromin) protein is a 2839 amino acid polypep-
tide, with a domain homologous to the catalytic domain of GTPase
activating proteins (GAPs) [28]. This domain, called the GAP-related
domain (GRD), regulates Ras activity by accelerating the conversion
of GTP-bound “active” Ras to its inactive GDP-bound form [29].
Previous studies have shown that reduced or absent Nf1 protein ex-
pression in neurofibrosarcoma cell lines results in high levels of the
active GTP-bound form of Ras (Ras-GTP) [30]. To determine
whether NF1 mutations and/or concomitant reduction of Nf1 ex-
pression are associated with increased levels of active Ras-GTP in
OSCs, an assay for activated Ras was performed in representative cell
lines. Cell lines with markedly reduced or absent Nf1 expression
(PEO4, A1847, CAOV3, DOV13, and OVCA429) had higher
Ras-GTP levels compared to the cell lines with robust expression
of Nf1 protein (Figure 6A). One OvCa line, HEY, which showed
readily detectable levels of Nf1 protein (Figure 3B), also manifested
high levels of active Ras-GTP.
A major consequence of Ras pathway activation is the phosphoryla-
tion of MAPK [31]. Hence, we examined our collection of primary
OSCs for the presence of active MAPK by immunohistochemistry
using an antibody directed against the active phosphorylated form of
p44/42 MAPK. As shown in Figure 6B and summarized in Table 2,
eight of nine primary OSCs with documented NF1 alterations showed
strong (++ or +++) pMAPK expression. Among the remaining OSCs
studied, ∼41% (12/29) also stained positively for pMAPK. In these
tumors, NF1 mutations may have been missed by our detection ap-
proach or MAPK may be activated by an alternative mechanism, such
as activating mutations of upstream signaling components, including
Table 1. NF1 Mutations Detected in OvCa Cell Lines and Primary Tumors by PTT.
ID cDNA Sequencing (NM_001042492, ATG as +1) Genomic DNA Sequencing Protein Change Mutation Type
PEO4 Del* c†291-481 (exon 4a) A478T (first nucleotide of exon 4b, NM_001042492) aa 97, PTC‡ at 109 Splicing
CAOV3 Del c3711-3977 (exons 22 and 23-1), c4110ins§102 bp Del 1448 bps (exons 22 and 23-2 and partial introns 21 to 23-2) aa1237, PTC 1245 deletion/splicing
OVCA429 Del c2943-2959 (exon 17) Del 2943-2959 (NM_001042492) aa 981, PTC 981 deletion
A1847 c4110 Ins101 bp from intron 23-2 C-G intron 23a (at 304314067 NT_010799) aa1371, PTC 1379 Splicing
DOV13 del c3873 -3977 (exon 23-1) 3974 (exon 23-1) + 1 (G to T) (NM_001042492) aa1291, PTC 1298 splicing
OSC-2 Duplication 662 bp (exons 24-27b) No mutation detected aa 1370, PTC 1379 splicing
OSC-18 Ins 178 bp (exons 44-45) No mutation detected aa 2602, PTC 2609 splicing
OSC-24 Del c5549-5751 (exon 30) Del 34 nucleotides 5′ exon 30, Ins ATG aa 1849, PTC 18451 deletion/splicing
OSC-25 Del c3711-3977 (exons 22 & 23-1) No mutation detected aa 1237, PTC 1245 splicing
OSC-32 Del exon 31 No mutation detected aa 1916, PTC 1921 splicing
OSC-35 Duplication 662 bp (exons 24-27b) No mutation detected aa 1370, PTC 1379 splicing
*Del = deletion.
†Sequence changes identified in cDNA are indicated by “c” before the number.
‡PTC = premature termination codon.
§Ins = insertion.
Figure 5. NF1 cDNA sequence alterations in representative cell
lines and primary tumors. Chromatograms showing (A) absence
of 17 bp of exon 17 from the cDNA of cell line OVCA429, (B) dele-
tion of exon 4a in cDNA from PEO4, (C) portion of 178 bp insertion
from intron 44 between exons 44 and 45 in tumor OSC-18, and (D)
deletion of exons 22 and 23-1 in cDNA from tumor OSC-25.
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the transmembrane receptor tyrosine kinase epidermal growth factor
receptor (EGFR), or HER-2/Neu.
OSCs with NF1 Defects Harbor Frequent Mutations in
TP53 But Not KRAS or BRAF
Previous studies provide evidence for two major pathways in the
pathogenesis of OSCs [32,33]. Low-grade OSCs are less common
but have a high prevalence of activating mutations of the KRAS or
BRAF proto-oncogenes and low prevalence of inactivating mutations
of the TP53 tumor-suppressor gene. Indeed, nearly 70% of low-
grade OSCs and their putative precursor lesions (serous borderline
tumors) have either KRAS or BRAF mutations [34,35]. In contrast,
high-grade OSCs comprise most OSCs, and in these tumors, KRAS
and BRAF mutations are rare, whereas TP53 mutations are common
[35,36]. We analyzed all 41 OSCs for mutations of TP53 (exons 3-
10), KRAS (codons 12 and 13), and BRAF (exons 11 and 15). None
of the OSCs had BRAF mutations, and only one tumor had a KRAS
mutation (Table 2). Immunostaining for p53 protein was also per-
formed in all but 1 of the 41 tumors (Table 2). Strong and diffuse
nuclear p53 expression of the type seen in tumors with missense
TP53 mutations was identified in 20 (50%) of 40 OSCs (data not
shown). To confirm the presence of missense mutations and to de-
tect mutations leading to loss or truncation of the p53 protein, TP53
exons 3-10 were sequenced. Overall, we identified TP53 mutations
in 30 (73%) of 41 tumors. Of these, 21 were missense, 4 were frame-
shift, and 5 were nonsense mutations. Notably, all nine tumors with
inactivated NF1 had documented TP53 mutations (Table 2). The
association between NF1 and TP53 mutations was statistically sig-
nificant (P = .041, 1-tail Fisher’s exact test) and there was a positive
correlation between mutations of NF1 and TP53 (r = 0.3211308, P =
.0406; Pearson’s product moment correlation).
Discussion
Although progress has been made in defining genetic alterations
underlying the pathogenesis of OvCa, including the identification
of specific mutations and gene expression patterns characteristic of
the various morphological subtypes of OvCa, much work would
seem to remain before we will have a full accounting of the key gene
defects contributing to the development of OvCa. Because genome-
wide analysis of DNA copy number alterations in primary OvCas
Figure 6. The Ras pathway is activated in ovarian carcinoma cell lines and primary OSCs. (A) Ras-GTP and total Ras levels in the ovarian
carcinoma cell lines were detected using a Ras activation assay kit as described in the Materials and Methods section. Representative
data are shown. The blot was reprobed with antiactin as a loading control. HCT116, which does not express NF1, and HEY, which
expresses mutant KRas (G12D), were used as a positive controls for Ras-GTP levels. Expression of Nf1 in each cell line [low or absent
(−) versus readily detectable (+)] is indicated below each lane. (B) Immunohistochemical analysis of pMAPK in primary OSCs; repre-
sentative examples are shown. OSC-32 (left panel) has a NF1mutation and shows strong nuclear staining for pMAPK in the tumor cells,
with absence of staining in the non-neoplastic stromal cells. No NF1 alterations were detected in OSC-33, which is negative for pMAPK
expression (right panel).
Neoplasia Vol. 10, No. 12, 2008 NF1 Mutations in Ovarian Serous Carcinomas Sangha et al. 1369
suggested the possibility of homozygous deletions of the NF1 gene in
a subset of OSCs, we pursued in-depth molecular analyses to assess
the frequency and mechanisms underlying NF1 inactivation in
OSCs. We provide data here that mutational defects leading to re-
duced or absent Nf1 expression were found in 5 of 18 OvCa cell
lines and 9 (22%) of 41 primary OSCs. In addition, given what is
known about the role of the Nf1 protein in negatively regulating
the activity of Ras proteins, we found, not unexpectedly, that OSCs
with NF1 mutations lacked KRAS or BRAF mutations. All tumors
with documented NF1 alterations were found to harbor mutations
of the TP53 tumor-suppressor gene.
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic
disorder affecting approximately 1 in 3000 individuals [37,38]. The
most common manifestations are café-au-lait macules, neurofibromas,
Lisch nodules, skin-fold freckling, bony dysplasia and learning disabil-
ities [38]. In addition to neurofibromas, those with neurofibromatosis
type 1 are at increased risk for development of other neoplasms, in-
cluding malignant peripheral nerve sheath tumors, gliomas, and gas-
trointestinal stromal tumors. Interestingly, coinactivation of TP53 by
deletion or by point mutation in conjunction with NF1 inactivation
has been shown to be a negative prognostic marker in NF1 patients
with malignant peripheral nerve sheath tumors [39,40]. A number
of studies have characterized germ line NF1 mutations in individ-
uals with neurofibromatosis type 1 and identified a diverse spectrum
of mutations that includes small deletions and insertions, missense
and nonsense point mutations, and mutations that affect splicing
[17,23,24,41–44]. There are no clear mutational hotspots. Because
more than 70% of NF1mutations are predicted to result in truncation
of the gene product [25], PTT has been widely used to screen for germ
line (constitutional) NF1 mutations.
The Ras proteins have central roles in the regulation of cell pro-
liferation and differentiation, and mutational activation of Ras sig-
naling contributes to the development of many types of cancer. Ras
proteins function as molecular switches in signaling pathways that
transmit signals from the cell membrane to the nucleus [31,45,46].
Ras cycles between the inactive GDP-bound and active GTP-bound
forms, signaling to downstream effectors that regulate basic cellular
functions including cell proliferation, differentiation, and apopto-
sis. Nf1 acts as a Ras-GTPase activating protein (Ras-GAP), which
catalyzes hydrolysis of Ras-GTP to Ras-GDP, with resultant down-
regulation of downstream signaling through Raf, Ral/Cdc42, PLC,
and PI3K. Loss of Nf1 function has been shown to deregulate Ras
Table 2. Summary of the Mutational Analysis and Immunohistochemistry in OSC Tissues.
Tumor ID Clinical Data ROMA-NF1 Deletions NF1 Mutations Type pMAPK (IHC) p53 (IHC) TP53 Mutations (Exon 3-10) KRAS Exon 2,3 BRAF Exon 11,15
Age Stage Grade Exon Nucleotide Codon Type
OSC-1 83 3C 3 homo Deletion +++ + 8 G824A C275Y Missense WT WT
OSC-2 61 4 3 hemi Splicing ++ + 5 A395G K132R Missense WT WT
OSC-3 43 3C 3 WT − + 7 A701G Y234C Missense WT WT
OSC-4 66 3C 3 WT − − WT WT WT
OSC-5 58 3B 2 hemi Deletion +++ + 5 C380T S127F Missense WT WT
OSC-6 57 3C 2 WT ++ − WT WT WT
OSC-7 44 3C 3 WT − − WT WT WT
OSC-8 57 3C 3 WT +++ + 5 A491G K164E Missense WT WT
OSC-9 67 1C 3 WT +++ + 5 T537G H179Q Missense WT WT
OSC-10 53 2C 2 WT ND + 5 A395G K132R Missense WT WT
OSC-11 60 4 2 homo Deletion +++ + 4 C215G P72R Missense WT WT
OSC-12 44 3D 3 WT − + 9 G976T E326stop Nonsense WT WT
OSC-13 67 4 1 WT − + 5 A395G K132R Missense WT WT
OSC-14 40 3C 2 WT ++ − 5 C499T Q167stop Nonsense WT WT
OSC-15 74 3C 3 WT + − 5 C497G S166stop Nonsense WT WT
OSC-16 67 3C 3 WT ++ + 6 C569T P190L Missense WT WT
OSC-17 62 3C 3 WT + − WT WT WT
OSC-18 59 1A 2 Splicing +++ − 7 746delG 344stop Frameshift WT WT
OSC-19 52 3 3 WT ND ND 7 C742T R248W Missense WT WT
OSC-20 65 2 3 WT +++ + 7 C725T C242F Missense WT WT
OSC-21 19 4 1 WT − − WT WT WT
OSC-22 30 4 1 WT − − WT WT WT
OSC-23 58 3C 2 WT − − 8 C916T R306Stop Nonsense WT WT
OSC-24 53 3C 2 hemi Deletion/splicing − + 8 C817G R273G Missense WT WT
OSC-25 58 3C 3 hemi Splicing +++ + 8 C844T R282W Missense WT WT
OSC-26 73 3C 2 WT − + 8 C844T R282W Missense WT WT
OSC-27 41 1C 2 WT ND − 7 689delC 246stop Frameshift WT WT
OSC-28 61 2C 1 WT − − 6 C637T R213Stop Nonsense WT WT
OSC-29 49 3C 1 WT ++ − WT G12R WT
OSC-30 42 3C 3 WT +++ − WT WT WT
OSC-31 50 3C 2 WT − − WT WT WT
OSC-32 54 3C 3 Splicing +++ + 5 G517A V173M Missense WT WT
OSC-33 60 3C 3 WT − − 6 C637T R213Stop Nonsense WT WT
OSC-34 61 3 1 WT +++ − WT WT WT
OSC-35 43 3C 3 Splicing +++ + 6 A659G Y220C Missense WT WT
OSC-36 56 4 3 WT − + 6 A659G Y220C Missense WT ND
OSC-37 48 3C 3 WT ++ + 6 T581G L194R Missense WT WT
OSC-38 68 1A 3 WT − − 7 689delC 246stop Frameshift WT WT
OSC-39 32 1B 1 WT ++ − WT WT WT
OSC-40 68 3C 3 WT ++ − 5 455delC 169stop Frameshift WT WT
OSC-41 73 3C 3 WT − + 8 G796A G266R Missense WT WT
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signaling in many types of cells, including Schwann cells, astrocytes,
hematopoietic cells, mast cells, and melanocytes [47–49]. Moreover,
NF1 mutations and/or loss of expression have been identified in
several different types of tumors, including melanomas, colorectal car-
cinomas, small cell lung carcinomas, and transitional cell carcinomas
[50–54]. Only a few studies in the published literature have addressed
the role of NF1 in ovarian cancer pathogenesis, and to the best of our
knowledge, no studies have described comprehensive analysis of NF1
mutations in ovarian cancers. Interestingly, Salud et al. [55] described a
29-year-old woman with neurofibromatosis type 1 who developed ep-
ithelial ovarian cancer.We believe ours is the first comprehensive study
undertaken to determine the frequency of NF1 mutations in a sizable
collection of OSC primary tumors and ovarian cancer cell lines.
We identified NF1 alterations in 5 (28%) of 18 ovarian carcinoma–
derived cell lines and 9 (22%) of 41 primary OSCs. Evidence for
biallelic inactivation of NF1 was obtained for six of the nine primary
tumors (three with homozygous deletion and three with hemizygous
deletion and mutation). The actual prevalence of inactivating NF1
mutations in OSCs is likely higher, because our mutation detection
strategy was based entirely on the PTT assay, which fails to detect a
third or more of NF1 mutations [42]. The high frequency of splicing
defects identified in our analysis is in keeping with other studies in
the published literature, which reported high rates of splicing muta-
tions in NF1 [41,42]. Although absence of matched normal tissue
precluded us from more definitively determining whether OSC tu-
mors or cell lines with mutations of one NF1 allele had allelic dele-
tions of the other copy, frequent allelic losses at the NF1 locus in
ovarian cancers have been reported by others [56,57].
As mentioned previously, a major consequence of Ras pathway ac-
tivation is the phosphorylation of MAPK. Notably, in their analysis
of active MAPK in OSC, Hsu et al. [58] showed that 41% of high-
grade OSCs expressed the active (phosphorylated) form of MAPK
(pMAPK) by immunohistochemistry, although KRAS or BRAF mu-
tations were not present in these tumors. Our findings confirm the
paucity of KRAS and BRAF mutations and suggest that MAPK
activation in OSCs may be largely attributable to Nf1 inactivation.
All but one of our OSCs with documented NF1 alterations expressed
pMAPK. Several additional tumors without demonstrable NF1 mu-
tations also highly expressed pMAPK, suggesting that these tumors
harbor NF1 mutations missed by PTT or mutations of other genes
upstream of MAPK, such as HER-2/Neu or EGFR.
Most studies have shown that ∼50% to 80% of “typical” (i.e.,
high-grade, high-stage) OSCs have mutations in TP53 [36,59,60].
Mutations of KRAS in these tumors are much less common (0-
12%), and BRAF mutations are extremely rare [33]. Our mutational
data are in agreement with these published reports. TP53 mutations
were detected in 30 (73%) of 41 primary OSCs. No BRAF muta-
tions were found, and only one tumor had mutant KRAS. The
co-occurrence of TP53 and NF1 mutations in our series of OSCs
suggests the pathways regulated by these two tumor-suppressor pro-
teins often cooperate in the development of ovarian carcinomas with
serous differentiation. Additional studies, for example, in genetically
engineered mice with conditionally mutant P53 and NF1 alleles, will
be required to test this possibility.
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Table W1. Primer Sequences.
Use Primer ID Sequences
Southern NF1 Probe 1-F CCTTCTTTGACTGTTGATGTAGT
NF1 Probe 1-R TTATGCAGGAATGGGTTATGGA
NF1 Probe 2-F AGAGCCTATGCGTTTTGAGAAGTATGAC
NF1 Probe 2-R TATTGGTGTTGGTTGTTTGGTGTTGTAG
NF1 Probe 3-F ACCAAGGCCTTCTCACTAACT







Sequencing Kras ex2-F GCCTGCTGAAAATGACTGAAT
Kras ex2-R GGTCCTGCACCAGTAATATGC
BRAF-ex11-F TCTCTTCCTGTATCCCTCTCAGGCA
BRAF-ex11-R CTTGTCACAATGTCACCACATTACA
BRAF-ex15-F CCTAAACTCTTCATAATGCTTGCTCTG
BRAF-ex15-R TAACTCAGCAGCATCTCAGGGCCAAA
TP53-5F TTTATCTGTTCACTTGTGCCC
TP53-5R ACCCTGGGCAACCAGCCCTG
TP53-6F CACTGATTGCTCTTAGGTCT
TP53-6R AGTTGCAAACCAGACCTCAGG
TP53-7F GCCACAGGTCTCCCCAAGGC
TP53-7R CAGTGTGCAGGGTGGCAAGT
TP53-8F GACCTGATTTCCTTACTGCC
TP53-8R CCACCGCTTCTTGTCCTGCT
PTT PTT-I-F GGATCCTAATACGACTCACTATAGGGAGACCACCATGATGGCCGCGCACAGGCCGGTGGAAT
PTT-I-R TGACAGGAACTTCTATCTGCCTGCTTA
PTT-II-F GGATCCTAATACGACTCACTATAGGGAGACCACCATGATGGTGAAACTAATTCATGCAGAT
PTT-II-R TGTCAAATTCTGTGCCTTG
PTT-III-F GGATCCTAATACGACTCACTATAGGGAGACCACCATGATGGAAGCAGTAGTTTCACTT
PTT-III-R TAGGACTTTTGTTCGCTCTGCTGA
PTT-IV-F GGATCCTAATACGACTCACTATAGGGAGACCACCATGGAGTACACCAAGTATCATGAG
PTT-IV-R TATACGGAGACTATCTAAAGTATGCAG
PTT-V-F GGATCCTAATACGACTCACTATAGGGAGACCACCATGATGGAGGCATGCATGAGAGATATTC
PTT-V-R TCTGCACTTGGCTTGCGGAT
